Notably, there is evidence that lenvatinib enhances the efficacy of anti-PD-1 treatment by inhibiting the FGFR4-glycogen synthase kinase 3β axis, promoting T-cell killing of HCC cells, and inhibiting Treg differentiation (Kudo et al., 2018). Here, PDCD1 is linked to hepatocellular carcinoma.